You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,588,895

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,588,895

Title:	Quinuclidine derivatives and medicinal compositions containing the same
Abstract:	Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane bromide.
Inventor(s):	Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee:	ALMIRALL, S.A. (Barcelona, ES)
Application Number:	16/045,333
Patent Claims:	1. A method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-- azoniabicyclo[2.2.2]octane bromide. 2. The method of claim 1, wherein the powder inhalant further comprises a pharmaceutically acceptable carrier or diluent. 3. The powder inhaler of claim 2, wherein the pharmaceutically acceptable carrier or diluent of the powder inhalant is lactose. 4. The method of claim 1, wherein the powder inhalant further comprises a .beta..sub.2 agonist. 5. The method of claim 4, wherein the powder inhalant further comprises a steroid or a phosphodiesterase IV inhibitor. 6. The method of claim 1, wherein the powder inhalant further comprises a steroid. 7. The method of claim 6, wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor. 8. The method of claim 1, wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor. 9. The method of claim 1 further comprising administering an effective amount of a .beta..sub.2 agonist. 10. The method of claim 9 further comprising administering an effective amount of a steroid or a phosphodiesterase IV inhibitor. 11. The method of claim 1 further comprising administering an effective amount of a steroid. 12. The method of claim 11 further comprising administering an effective amount of a phosphodiesterase IV inhibitor. 13. The method of claim 1 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.